CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cisplatin

顺铂 杂质对照品Cisplatin Impurities

EP17 个杂质条目17 impurity entries

本页汇总 顺铂 的 17 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 17 impurity reference standards of Cisplatin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 顺铂(Cisplatin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesLactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer
    Cancer letters · 2026 · Yu K et al.  ·  PMID 41621475  ·  DOI
  2. 杂质研究Impurity studiesGenotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study
    Interdisciplinary toxicology · 2019 · Azab B et al.  ·  PMID 32206030  ·  DOI
  3. 杂质研究Impurity studiesNanoparticle formulations of cisplatin for cancer therapy
    Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016 · Duan X et al.  ·  PMID 26848041  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process
    Pharmaceutics · 2024 · Sharma SK et al.  ·  PMID 39598594  ·  DOI
  • 合成方法SynthesisOne-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy
    Theranostics · 2020 · Zhang X et al.  ·  PMID 32194844  ·  DOI

顺铂 —— 原料药与杂质对照品Cisplatin — drug substance & impurities

共 18 个条目(含原料药本体)18 items incl. the drug substance
Cisplatin structure
EP原料药 APIAPI
顺铂Cisplatin
Cisplatin
CAS No.15663-27-1
Chemical FormulaCl2H6N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 3 (Cisplatin EP Impurity B) structure
EPB
顺铂杂质3 (顺铂EP杂质B)Cisplatin Impurity 3 (Cisplatin EP Impurity B)
Cisplatin Impurity 3 (Cisplatin EP Impurity B)
CAS No.13820-91-2
Chemical FormulaCl3H3KNPt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 3 Monomer (Cisplatin EP Impurity B Monomer) structure
EPB
顺铂杂质3单体 (顺铂EP杂质B单体)Cisplatin Impurity 3 Monomer (Cisplatin EP Impurity B Monomer)
Cisplatin Impurity 3 Monomer (Cisplatin EP Impurity B Monomer)
CAS No.17632-41-6
Chemical FormulaCl3H3NPt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 3 Monomer-15N (Cisplatin EP Impurity B Monomer-15N) structure
EPB
顺铂杂质3单体-15N (顺铂EP杂质B单体-15N )Cisplatin Impurity 3 Monomer-15N (Cisplatin EP Impurity B Monomer-15N)
Cisplatin Impurity 3 Monomer-15N (Cisplatin EP Impurity B Monomer-15N)
CAS No.738536-98-6
Chemical FormulaCl3H315NPt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 4 Dipotassium Salt (Cisplatin EP Impurity C Dipotassium Salt) structure
EPC
顺铂杂质4 二钾盐 (顺铂EP杂质C 二钾盐)Cisplatin Impurity 4 Dipotassium Salt (Cisplatin EP Impurity C Dipotassium Salt)
Cisplatin Impurity 4 Dipotassium Salt (Cisplatin EP Impurity C Dipotassium Salt)
CAS No.10025-99-7
Chemical FormulaCl4Pt2-·2k+
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 4 (Cisplatin EP Impurity C) structure
EPC
顺铂杂质4 (顺铂EP杂质C)Cisplatin Impurity 4 (Cisplatin EP Impurity C)
Cisplatin Impurity 4 (Cisplatin EP Impurity C)
CAS No.13965-91-8
Chemical FormulaCl4Pt2-
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 1 structure
1
顺铂杂质1Cisplatin Impurity 1
Cisplatin Impurity 1
CAS No.53861-42-0
Chemical FormulaClH8N2OPt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 2 (Transplatin) structure
2
顺铂杂质2 (反铂)Cisplatin Impurity 2 (Transplatin)
Cisplatin Impurity 2 (Transplatin)
CAS No.14913-33-8
Chemical FormulaCl2H6N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 5 Monomer structure
5
顺铂杂质5单体Cisplatin Impurity 5 Monomer
Cisplatin Impurity 5 Monomer
CAS No.62048-57-1
Chemical FormulaH14N4O2Pt22+
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 5 structure
5
顺铂杂质5Cisplatin Impurity 5
Cisplatin Impurity 5
CAS No.62048-58-2
Chemical FormulaH14N4O2Pt22+·2(NO3-)
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 6 structure
6
顺铂杂质6Cisplatin Impurity 6
Cisplatin Impurity 6
CAS No.15978-93-5
Chemical FormulaH6I2N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 7 structure
7
顺铂杂质7Cisplatin Impurity 7
Cisplatin Impurity 7
CAS No.41575-87-5
Chemical FormulaH6N4O6Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 9 structure
9
顺铂杂质9Cisplatin Impurity 9
Cisplatin Impurity 9
CAS No.14708-56-6
Chemical FormulaI4K2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 10  Dinitrate structure
10
顺铂杂质10 双硝酸盐Cisplatin Impurity 10 Dinitrate
Cisplatin Impurity 10 Dinitrate
CAS No.20634-12-2
Chemical FormulaH12N4Pt2+·2(NO3-)
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 14 structure
14
顺铂杂质14Cisplatin Impurity 14
Cisplatin Impurity 14
CAS No.33518-19-3
Chemical FormulaH9IN3Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 15 structure
15
顺铂杂质15Cisplatin Impurity 15
Cisplatin Impurity 15
CAS No.15978-94-6
Chemical FormulaH6I2N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 16 structure
16
顺铂杂质16Cisplatin Impurity 16
Cisplatin Impurity 16
CAS No.112837-72-6
Chemical FormulaCl2H8N2O2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Cisplatin Impurity 18 structure
18
顺铂杂质18Cisplatin Impurity 18
Cisplatin Impurity 18
CAS No.16893-05-3
Chemical FormulaCl4H6N2Pt
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

顺铂 —— 研究文献与合成路线Cisplatin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 顺铂 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cisplatin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. The deubiquitinase USP44 enhances cisplatin chemosensitivity through stabilizing STUB1 to promote LRPPRC degradation in neuroblastoma
    Zeng L, Li YQ, He SW, et al. · Neuro-oncology · 2025 · 被引 14cited 14
  2. Cisplatin induces kidney damage through the down-regulation of Prx I by autophagic degradation
    Park J, Sim J, Yi HJ, et al. · Free radical biology & medicine · 2024 · 被引 7cited 7
  3. CHIP drives proteasomal degradation of NUR77 to alleviate oxidative stress and intrinsic apoptosis in cisplatin-induced nephropathy
    Zhang H, Deng Z, Wang Y, et al. · Communications biology · 2024 · 被引 2cited 2
  4. EBV (LMP1) enhances cisplatin resistance by enhancing degradation of interferon regulatory factor 3
    Li Y, Liu N, Yang C, et al. · Cell communication and signaling : CCS · 2026 · 被引 1cited 1
  5. ATP6V0D2 drives triple-negative breast cancer progression and inhibits cisplatin sensitivity by promoting PHLPP2 lysosomal degradation
    Zhang J, Cao C, Yang H, et al. · iScience · 2025 · 被引 1cited 1
  6. Resveratrol Induces Proteasomal Degradation of PTPN1 to Enhance Cisplatin Sensitivity in Epstein-Barr Virus-Associated Malignancies
    Liu N, Li Y, Tang M, et al. · Pharmaceuticals (Basel, Switzerland) · 2026

合成与制备工艺专利Synthesis & process patents

  1. Peptide - cisplatin conjugate and preparation method and application thereof
    LINQUAN ZANG · 公开号 CN101870726CN101870726 · 2010
  2. Cisplatin nano-micelle prodrug and preparation method thereof
    JIAHUI YU, XIAOXING TANG, XINCHENG SHEN, DANNONG HE, et al. · 公开号 CN101590241CN101590241 · 2009
  3. Method for synthesizing antineoplastic medicine cisplatin
    YANWEI CONG, SHAOPING PU, JUAN PENG, CHUANZHU GAO, et al. · 公开号 CN101234788CN101234788 · 2008
  4. Cisplatin polymer micelle preparation method and use thereof
    JIAHUI YU, CHENGYUN WANG, SHUNYING LIU, SHUFANG LUO · 公开号 CN101455843CN101455843 · 2009
  5. CISPLATIN PREPARATION AND PROCESS FOR PRODUCING THE SAME
    INOUE Fujio, IZUMI Masamitsu, OKAMOTO Hideshi · 公开号 WO2004112778WO2004112778 · 2004

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

顺铂 杂质谱研究要点Cisplatin — impurity profiling notes

下面这些是拿到 顺铂 的 18 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 18 impurity entries for Cisplatin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances